Pharma & Legal
Pfizer secures deals to delay generic competition
By Intent.Health Team • April 28, 2026
What’s happening
Pfizer secured agreements to keep a key heart drug protected from generic competition until 2031.
What’s changing / Business impact
-
Extends revenue lifecycle of blockbuster drug.
-
Delays entry of: lower-cost generics.
-
Strengthens pricing power in the short term.
Why this matters
Pharma revenue is heavily influenced by patent protection timelines.
This shows:
-
Companies actively manage exclusivity windows.
-
Market competition is shaped by legal strategy, not just innovation.
-
Drug affordability and access are tied to patent dynamics.